[Clinical Study of Different Doses of Glucocorticoids in the Treatment of Severe <i>Mycoplasma pneumoniae</i> Pneumonia in Children].
摘要
Objective: pneumonia (SMPP) treated with different doses of glucocorticoids (GC) and to investigate factors associated with GC treatment efficacy on the basis of propensity score matching (PSM). Methods: = 142) on the basis of clinical treatment outcomes, and multivariate logistic regression was conducted to determine risk factors for clinical GC treatment failure. Results: > 0.05). Multivariate analysis showed that RMPP and high peak fever were independent risk factors for GC treatment failure. Conclusion: High-dose GC therapy may facilitate fever resolution, shorten the duration of fever, and enhance radiological improvement. However, its overall efficacy is not significantly superior to low-dose therapy and is associated with a higher incidence of adverse reactions. Younger age, atelectasis, and elevated platelet count are key factors influencing the use of high-dose GC in children. Notably, RMPP and high peak fever are independent risk factors for GC treatment failure, irrespective of the GC dosage. Clinicians should carefully evaluate the individualized risk-benefit profile when considering high-dose GC therapy for pediatric SMPP.